What is oxymorphone HCl ER, and what is it used for?
Oxymorphone hydrochloride extended-release (HCl ER) is a prescription opioid medicine made to release oxymorphone slowly over time. It’s used to manage chronic, around-the-clock pain that requires daily, long-term opioid treatment and cannot be adequately managed with other pain medicines.
How does extended-release oxymorphone work?
Oxymorphone is an opioid agonist that acts on opioid receptors in the brain and spinal cord to reduce pain signaling. The ER (extended-release) formulation is designed to maintain steadier blood levels during the day, rather than producing a fast peak the way immediate-release products do.
How should extended-release oxymorphone be taken (and what are common mistakes)?
Because it is extended-release, it must be swallowed whole. Crushing, chewing, or breaking an ER tablet can cause the medicine to release too quickly, which increases the risk of overdose and other serious side effects.
Patients should also avoid combining it with other sedating drugs or alcohol unless a clinician specifically approves it, since opioid-related respiratory depression risk goes up.
What side effects are most commonly associated with oxymorphone ER?
Common opioid side effects include sleepiness, dizziness, nausea/vomiting, constipation, and itching. The most serious risk is slowed or stopped breathing (respiratory depression), especially at higher doses or when combined with other depressants.
What precautions matter for safety?
Key risks include opioid dependence and withdrawal, overdose, and dangerous breathing problems. Extra caution is needed for people with breathing disorders (such as sleep apnea or COPD), older adults, and those with liver problems. Clinicians also consider drug interactions that can increase sedation or opioid levels.
Is there a generic or patent information for oxymorphone ER?
For patent and exclusivity research (including company and filing details) related to oxymorphone ER products, DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/